Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Impedimed Limited ( (AU:IPD) ) has provided an update.
ImpediMed has secured firm commitments for a A$13.2 million two‑tranche institutional placement at A$0.010 per share, supported by new and existing investors and directors, and will launch a share purchase plan of up to A$2.0 million for eligible shareholders. Each new share under both offers carries free attaching options, and the proceeds will be used to partially prepay its SWK Growth Capital Facility, bolster working capital, and fund the commercial scaling of its SOZO platform, particularly in the U.S. market.
Alongside the capital raise, the company will implement initiatives delivering at least A$5.0 million in annualised cost reductions by July 2026, which, together with the new funding, is expected to provide sufficient capital for its growth plans and a pathway to operating cash flow breakeven in FY28 assuming full option exercise. The transaction follows a quarter of growing recurring revenue, broader U.S. reimbursement coverage for BCRL, initial sales in heart health and weight management, and the recent appointment of CEO Erik Anderson, underscoring management’s focus on balance sheet strength, disciplined execution and restoring shareholder value.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is an Australian medical technology company listed on the ASX that develops and commercialises its SOZO bioimpedance spectroscopy platform. The company focuses on applications such as breast cancer-related lymphoedema (BCRL) monitoring, with a growing presence in the key U.S. market and expansion into heart health and weight management segments.
YTD Price Performance: -58.82%
Average Trading Volume: 4,907,406
Technical Sentiment Signal: Sell
Current Market Cap: A$28.54M
Learn more about IPD stock on TipRanks’ Stock Analysis page.